NuPathe's Zelrix first transdermal patch for migraine to undergo FDA review
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review the new drug application (NDA) for NuPathe's Zelrix (sumatriptan transdermal), which is the first investigational transdermal patch for migraine ever reviewed by the agency.